| Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery J Cory Kalvass, TS Maurer Biopharmaceutics & drug disposition 23 (8), 327-338, 2002 | 456 | 2002 |
| Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches NA Hosea, WT Collard, S Cole, TS Maurer, RX Fang, H Jones, SM Kakar, ... The Journal of Clinical Pharmacology 49 (5), 513-533, 2009 | 304 | 2009 |
| Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and … AS Kalgutkar, RS Obach, TS Maurer Current drug metabolism 8 (5), 407-447, 2007 | 271 | 2007 |
| Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios JC Kalvass, TS Maurer, GM Pollack Drug metabolism and disposition 35 (4), 660-666, 2007 | 258 | 2007 |
| Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice TS Maurer, DB DeBartolo, DA Tess, DO Scott Drug metabolism and disposition 33 (1), 175-181, 2005 | 248 | 2005 |
| Volume of distribution in drug design: miniperspective DA Smith, K Beaumont, TS Maurer, L Di Journal of medicinal chemistry 58 (15), 5691-5698, 2015 | 235 | 2015 |
| A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro OA Fahmi, TS Maurer, M Kish, E Cardenas, S Boldt, D Nettleton Drug Metabolism and Disposition 36 (8), 1698-1708, 2008 | 208 | 2008 |
| Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction SL Ripp, JB Mills, OA Fahmi, KA Trevena, JL Liras, TS Maurer, ... Drug Metabolism and disposition 34 (10), 1742-1748, 2006 | 152 | 2006 |
| Relevance of half-life in drug design: Miniperspective DA Smith, K Beaumont, TS Maurer, L Di Journal of medicinal chemistry 61 (10), 4273-4282, 2017 | 134 | 2017 |
| Discovery of a clinical candidate from the structurally unique dioxa-bicyclo [3.2. 1] octane class of sodium-dependent glucose cotransporter 2 inhibitors V Mascitti, TS Maurer, RP Robinson, J Bian, CM Boustany-Kari, T Brandt, ... Journal of medicinal chemistry 54 (8), 2952-2960, 2011 | 130 | 2011 |
| Clearance in drug design: miniperspective DA Smith, K Beaumont, TS Maurer, L Di Journal of Medicinal Chemistry 62 (5), 2245-2255, 2018 | 119 | 2018 |
| PF-1355, a mechanism-based myeloperoxidase inhibitor, prevents immune complex vasculitis and anti–glomerular basement membrane glomerulonephritis W Zheng, R Warner, R Ruggeri, C Su, C Cortes, A Skoura, J Ward, K Ahn, ... Journal of Pharmacology and Experimental Therapeutics 353 (2), 288-298, 2015 | 85 | 2015 |
| Influence of microsomal concentration on apparent intrinsic clearance: implications for scaling in vitro data JC Kalvass, DA Tess, C Giragossian, MC Linhares, TS Maurer Drug metabolism and disposition 29 (10), 1332-1336, 2001 | 76 | 2001 |
| A “middle-out” approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling R Li, HA Barton, PD Yates, A Ghosh, AC Wolford, KA Riccardi, TS Maurer Journal of pharmacokinetics and pharmacodynamics 41, 197-209, 2014 | 73 | 2014 |
| In silico modeling of nonspecific binding to human liver microsomes H Gao, L Yao, HW Mathieu, Y Zhang, TS Maurer, MD Troutman, DO Scott, ... Drug metabolism and disposition 36 (10), 2130-2135, 2008 | 72 | 2008 |
| Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl) pyrazine, a novel 5-hydroxytryptamine2c receptor agonist for the treatment of obesity: role of metabolic activation AS Kalgutkar, DK Dalvie, J Aubrecht, EB Smith, SL Coffing, JR Cheung, ... Drug metabolism and disposition 35 (6), 848-858, 2007 | 65 | 2007 |
| Rapid Method to Determine Intracellular Drug Concentrations in Cellular Uptake Assays: Application to Metformin in OCT1-transfected HEK Cells HC Chien, AA Zur, TS Maurer, SW Yee, J Tolsma, P Jasper, DO Scott, ... Drug Metabolism & Disposition 44 (3), 356-364, 2016 | 61 | 2016 |
| Impact of recovery on fraction unbound using equilibrium dialysis L Di, JP Umland, PE Trapa, TS Maurer Journal of pharmaceutical sciences 101 (3), 1327-1335, 2012 | 60 | 2012 |
| Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based … RB Ruggeri, L Buckbinder, SW Bagley, PA Carpino, EL Conn, ... Journal of medicinal chemistry 58 (21), 8513-8528, 2015 | 54 | 2015 |
| PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy S Orena, TS Maurer, L She, R Eudy, V Bernardo, D Dash, P Loria, ... Frontiers in pharmacology 4, 115, 2013 | 54 | 2013 |
Avijit GhoshJohnson and JohnsonVerified email at its.jnj.com
